<DOC>
	<DOCNO>NCT01121380</DOCNO>
	<brief_summary>The purpose study test safety , tolerability pharmacokinetics BL-1021 healthy volunteer . Subsequent clinical study design test safety efficacy BL-1021 patient neuropathic pain base data obtain proposal trial describe .</brief_summary>
	<brief_title>A Study Intended Evaluate Safety , Tolerability Pharmacokinetics ( PK ) Parameters BL-1021</brief_title>
	<detailed_description>A total 32 subject single-ascending phase 24 subject multiple ascend phase , provide write informed consent comply inclusion/exclusion criterion participate study 4 different cohort first phase ( cohorts A , B , C D ) 3 different cohort second phase ( cohort E , F G ) , consist 8 subject . First part dosing : Cohort A - 10 mg Cohort B - 20 mg Cohort C - 30 mg Cohort D - 40 mg Second part dosing : Cohort E - X mg ( X shall determine use result 1st part ) Cohort F - 2X mg Cohort G - 4X mg</detailed_description>
	<criteria>The inclusion criterion part 1 2 study : Ability provide write informed consent Healthy male 18 45 year age , inclusive BMI 1830 , inclusive Negative urinary drug abuse screen within 21 day start study No significant abnormal blood hematology biochemistry test accord opinion principal investigator Only subject know ( prestudy ) CYP2D6 genotype enrol . No concomitant medication ( prescription , OTC , vitamin , dietary supplement ) within 7 day prior administration study medication Nonsmoking ( declaration ) period least 6 month prior enrolment Ability adhere visit schedule protocol requirement available complete study No significant abnormality physical examination Exclusion criterion part 1 2 study : Evidence history significant concomitant disease ( include mental , CNSrelated , renal , hepatic , cardiovascular , pulmonary disease , ) Prior current history cancer , except cure basal cell carcinoma skin History significant abnormality ECG , include QT prolongation History significant neurological , renal , cardiovascular , respiratory ( asthma ) , endocrinological , gastrointestinal , hematopoietic disease , neoplasm ( especially melanoma ) , clinically significant medical disorder , Investigator 's judgment contraindicate administration study medication Use another investigational medication/treatment past 30 day History drug alcohol abuse Significant abnormalities screen physical examination Significant abnormalities clinical laboratory parameter ( hematology , biochemistry , serology , urinalysis ) History gastrointestinal disorder likely influence drug absorption Consumption SerotoninNorepinephrine Reuptake Inhibitors ( SNRI 's ) , selective serotonin reuptake inhibitor ( SSRI 's ) , tricyclic/tetracyclic antidepressant within 90 day prior Day 0 Consumption drug may potentially inhibit induce liver cytochrome P450 activity within 3 week prior Day 0 Subjects either extensiveextensive metabolizers ( i.e . carrier multiple CYP2D6 gene copy ) poor metabolizers CYP 2D6 exclude . Any acute medical situation ( e.g . acute infection ) within 48 hour Day 0 , consider significance Principal Investigator Unusual diet Seropositive HIV , HBSAg HCV Donation 450ml blood within previous 12 week Probability undertake intense physical activity throughout study duration ( Single Dose : Day 0 Day 8 , Multiple Dose : Day 0 Day 14 ) Any condition , opinion Principal Investigator would place subject risk influence conduct study interpretation result Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) Subjects , judgment investigator , likely noncompliant uncooperative unwilling sign consent form</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Volunteers</keyword>
</DOC>